Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Multiplace Series
Hard-Shell Multiplace·2-18+ person
Pressure3 ATA
$150,000 - $400,000+
●●●○Moderate Evidence
Hyperbaric Therapy for Acute COVID-19 Hypoxia
Emergency HBOT protocols during the COVID pandemic showed reduced ventilator need and ICU mortality. This is distinct from long COVID — a separate indication.
Hyperbaric oxygen therapy (HBOT) for COVID-19 (Acute Hypoxia) has moderate clinical evidence. This is currently an off-label use and is not covered by insurance. The recommended protocol is 2.0–2.4 ATA (acute hypoxia); 1.5 ATA (subacute) ATA for 60–90 minutes per session per session over 5–10 sessions sessions.
Key Takeaways
- HBOT delivers oxygen directly in plasma — bypassing COVID-damaged lungs — maintaining tissue oxygenation independent of alveolar function
- Thibodeaux et al. (2021): 20 COVID patients treated with HBOT at Houston Methodist — improved SpO2, majority avoided mechanical ventilation
- Gorenstein et al. (2021): 10-session HBOT protocol showed significant SpO2 improvements in 20 COVID patients
- Hospital-based emergency indication — not appropriate for home or outpatient use during active infection
- Distinct from long COVID HBOT: different mechanism, protocol, patient population, and evidence base
What is COVID-19 (Acute Hypoxia)?
During the COVID-19 pandemic, a small number of hyperbaric units worldwide deployed HBOT as an emergency intervention for patients with severe COVID-related hypoxia who were deteriorating but had not yet required mechanical ventilation. The rationale was straightforward: COVID-19 pneumonia causes profound hypoxia by damaging alveolar tissue and triggering an inflammatory cascade. HBOT can dramatically increase dissolved oxygen in blood plasma independent of lung function, potentially maintaining tissue oxygenation while allowing time for the inflammatory process to resolve. Multiple case series and small trials published in 2020–2021 reported encouraging results: reduced need for mechanical ventilation, shorter ICU stays, and improved oxygen saturation in patients who received HBOT as a bridge intervention. These were emergency conditions with high mortality risk, so the bar for intervention was different than in elective HBOT settings. Importantly, this indication — acute COVID-19 hypoxia — is distinct from long COVID (post-acute sequelae of SARS-CoV-2 infection, or PASC), which is a separate condition with its own evidence base and condition page. Acute COVID-19 HBOT is a hospital-based emergency intervention; long COVID HBOT is typically an elective outpatient protocol. The pandemic context also means this indication has limited post-pandemic clinical infrastructure — most acute COVID cases no longer reach the severity that prompted emergency HBOT deployment.
How Hyperbaric Therapy Helps COVID-19 (Acute Hypoxia)
COVID-19 pneumonia impairs the lung's ability to transfer oxygen to blood — even with supplemental oxygen, severely affected patients cannot maintain adequate blood oxygen levels. HBOT bypasses this impaired gas exchange by dissolving oxygen directly in plasma at levels 10–15 times normal, independent of hemoglobin or alveolar function. This mechanism provides: immediate correction of life-threatening hypoxia without mechanical ventilation (which carries significant risks including ventilator-associated pneumonia and barotrauma), reduction of systemic inflammation through HBOT's anti-inflammatory mechanisms, potential reduction in cytokine storm severity, and improved oxygen delivery to hypoxic organs beyond the lungs (heart, kidneys, brain). The anti-inflammatory effects of HBOT may be particularly relevant given that severe COVID-19 mortality is largely driven by immune dysregulation rather than direct viral damage.
Recommended Protocol
Pressure
2.0–2.4 ATA (acute hypoxia); 1.5 ATA (subacute)
Sessions
5–10 sessions
Duration
60–90 minutes per session
What Does the Evidence Say?
●●●○Moderate Evidence
Thibodeaux et al. (2021) published a case series of 20 COVID-19 patients treated with HBOT at Houston Methodist Hospital: all patients showed improved oxygen saturation, and the majority avoided mechanical ventilation. Gorenstein et al. (2021) reported a prospective observational study of 20 COVID patients receiving 10 HBOT sessions — significant improvements in SpO2 and clinical status were documented. Multiple hospital protocols from the US, Israel, and Turkey reported similar findings during 2020–2021. Limitations are significant: these are small observational studies conducted under emergency conditions without robust control groups. The standard of care for severe COVID-19 evolved rapidly during this period (remdesivir, dexamethasone, prone positioning), making historical controls unreliable. A randomized trial (Kjeldsen et al., NCT04386616) was initiated but enrollment challenges limited its scope. The evidence is encouraging but not definitive. Current relevance is primarily for hyperbaric units in hospital settings capable of treating COVID patients acutely — not for outpatient or home use.
Off-Label Use
COVID-19 (Acute Hypoxia) is not an FDA-approved indication for HBOT. Treatment is considered off-label and is typically not covered by insurance. Consult your physician before starting any HBOT protocol.
Recommended Chambers for COVID-19 (Acute Hypoxia)
Based on the protocol requirements — minimum 2 ATA, Clinical Grade tier. Sorted by clinical credibility score.
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 34
Hard-Shell Monoplace·1-person
Pressure3 ATA
$50,000 - $90,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 36
Hard-Shell Monoplace·1-person
Pressure3 ATA
$55,000 - $95,000
Clinical GradeFDA Cleared
For Maximum Comfort
Perry Baromedical
Sigma 40
Hard-Shell Monoplace·1-person
Pressure3 ATA
$65,000 - $110,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 40-II
Hard-Shell Multiplace·2-person
Pressure3 ATA
$100,000 - $160,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma Elite
Hard-Shell Monoplace·1-person
Pressure3 ATA
$80,000 - $130,000
Frequently Asked Questions
What is the difference between acute COVID-19 HBOT and long COVID HBOT?
Acute COVID-19 HBOT is an emergency hospital intervention for patients with severe hypoxia during active COVID-19 infection — the goal is to prevent ventilator need and maintain oxygen levels while the infection runs its course. Long COVID HBOT addresses the persistent symptoms (fatigue, brain fog, dysautonomia) that remain weeks to months after acute infection resolves. The mechanisms, protocols, settings, and patient populations are entirely different. Long COVID has its own dedicated condition page with a separate evidence base — including Israeli RCT evidence (Efrati et al.). If you are looking for post-infection symptom treatment, see the long COVID page.
Is HBOT relevant for COVID-19 treatment in 2025–2026?
The acute COVID-19 indication is largely a pandemic-era intervention. Severe COVID hypoxia still occurs, but widespread vaccination and antiviral treatments (Paxlovid, molnupiravir) have dramatically reduced the rate of severe respiratory failure. Hospital hyperbaric units retain the capability to deploy HBOT for severe COVID hypoxia, but it is rarely needed now. The more active clinical area is long COVID, where elective outpatient HBOT protocols continue to be studied and offered.
Can I use HBOT at home to treat COVID-19?
No — acute COVID-19 hypoxia is a medical emergency requiring hospital management. Home chambers (even hard-shell advanced-wellness units) are not appropriate for treating patients with severe hypoxia, who need cardiac monitoring, oxygen saturation tracking, and emergency medical support during sessions. If you or someone you know has severe COVID-related breathing difficulty, this is a hospital emergency — call 911 or go to the nearest emergency department.
Which hospitals offer HBOT for COVID-19?
During the pandemic, hyperbaric units at major academic medical centers deployed COVID-HBOT protocols — Houston Methodist, NYU Langone, Mayo Clinic, and several Israeli and Turkish centers were among those publishing results. Today, most hospital hyperbaric units retain the capability but rarely use it for COVID specifically. If you are currently hospitalized with severe COVID and interested in HBOT, ask your treating physician whether the hospital has a hyperbaric unit and whether HBOT is appropriate for your clinical situation.
Was HBOT studied in a randomized controlled trial for COVID-19?
Yes — a randomized trial was initiated (ClinicalTrials.gov NCT04386616), but pandemic logistics, rapidly evolving standard of care, and enrollment challenges limited its scope and statistical power. The published COVID-HBOT evidence is primarily case series and prospective observational studies, which showed encouraging results but cannot establish causation with the rigor of a well-powered RCT. This is a recognized limitation of COVID-HBOT evidence.
Related Conditions
Sources & References
- Thibodeaux et al. (2021) — Hyperbaric oxygen therapy for COVID-19 severe hypoxemia, Journal of Emergency Medicine
- Gorenstein et al. (2021) — Hyperbaric oxygen therapy for COVID-19 patients with respiratory failure, Advances in Experimental Medicine and Biology
- Kjeldsen et al. (2021) — Pilot trial of hyperbaric oxygen therapy for patients with COVID-19, BMJ Open
- Guo et al. (2020) — Hyperbaric oxygen therapy may be effective to improve hypoxemia in patients with severe COVID-19 pneumonia, Frontiers in Medicine
Last updated: March 2026. Data sourced from manufacturer specifications, FDA databases, and published clinical research.
Ready to compare chambers?
Use our filterable directory to find chambers that match your protocol requirements.